Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6391427 | 0.85 | AVPR1A (0.43) | SIGMAR1AVPR1A | |
| SCHEMBL6390882 | 0.82 | NPC1 (0.47) | NPC1KMT2ATLR9SIGMAR1 | |
| SCHEMBL5285381 | 0.78 | KMT2A (0.58) | NPC1KMT2ATLR9 | |
| SCHEMBL5281210 | 0.76 | AVPR1A (0.46) | AVPR1A | |
| SCHEMBL19608944 | 0.74 | ALDH1A1 (0.58) | KMT2ASIGMAR1 | |
| SCHEMBL5244644 | 0.71 | KMT2A (0.62) | NPC1KMT2ATLR9 | |
| SCHEMBL5343964 | 0.71 | AVPR1A (0.47) | SIGMAR1AVPR1A | |
| SCHEMBL6392857 | 0.71 | KMT2A (0.60) | NPC1KMT2A | |
| SCHEMBL15963350 | 0.70 | ALDH1A1 (0.54) | KMT2ASIGMAR1 | |
| SCHEMBL8268564 | 0.69 | AVPR1A (0.39) | SIGMAR1AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | NPC1 1567/4885KMT2A 1303/4885TLR9 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.